Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SU-011, 248 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SU-011,248 | DRUG | - |
Inclusion Criteria: * Eligible patients must be at least 18 years of age with a diagnosis of metastatic kidney cancer. * The patient's kidney cancer must have gotten worse during/after previous cytokine-based therapy was given. * Any side effects from prior therapy must have subsided, and blood and...
SU-011,248 is an investigational small molecule being studied for the treatment of kidney neoplasms, specifically advanced kidney cancer. It is being evaluated in adult patients with this condition. The drug is currently in Phase 2 clinical development and is not yet approved for any use.
SU-011,248 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced kidney cancer.
SU-011,248 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for the treatment of kidney neoplasms, and its clinical trial program is ongoing to assess its safety and efficacy.
SU-011,248 has been studied in a Phase 2 clinical trial identified as NCT00054886, titled 'Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer.' This trial, which enrolled 63 participants in the United States, has been completed. The study was uncontrolled and not randomized or double-blinded.
SU-011,248 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of kidney neoplasms. The drug has been studied in a completed clinical trial, but it has not received regulatory approval for any indication.